ABLC community
ABLC community

Primogene raises €4.1M for breast milk protein

Jim Lane May 4, 2026
0 Comments

In Germany, start-up Primogene GmbH has raised €4.1 million (US$4.7 million) in funding to bring complex bioactive molecules to market at scale for applications that include infant nutrition and personal care. 

Primogene has developed a scalable process to produce disialyllacto-N-tetraose, a structurally complex human milk oligosaccharide with significant clinical benefits for premature infants, as well as a family of fucosylated lacto-N-tetraose molecules, including difucosyllacto-N-tetraose I (LNDFH I), the HMO with the second-highest concentration in breast milk.

The new capital will be used to expand Primogene’s IP portfolio, strategic partnerships, and production capacities. 

The seed round was led by High-Tech Gründerfonds with additional investors including Technologiegründerfonds Sachsen, better ventures, Sächsische Beteiligungsgesellschaft, Golzern Holding GmbH, FS Life Science Investment GmbH, and Dr. Marc Struhalla (founder and CEO of c-LEcta GmbH). 

Categories: Uncategorized

Related Articles

Responses

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .